Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma

NCT03008369 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03008369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03008369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2017
Completion date
September 28, 2022
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant adrenal gland pheochromocytoma, malignant paraganglioma, metastatic adrenal gland pheochromocytoma